What is the 13F Pro Quality Score for NRXS?

13F Pro ranks Neuraxis, INC (NRXS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NRXS's current score at https://13fpro.ai/research/NRXS (free sign-up required for the full ranking).

Where does 13F Pro source NRXS data?

All Neuraxis, INC fundamentals and ownership data come directly from SEC EDGAR. Neuraxis, INC files with the SEC under CIK 1933567. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NRXS in?

Neuraxis, INC (NRXS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NRXS research updated on 13F Pro?

NRXS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Neuraxis, INC(NRXS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1933567 NRXS stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $3.6M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

NRXS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Neuraxis, INC (NRXS), a Healthcare sector company. NRXS is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $3.6m in revenue. Based on the latest XBRL financial filings (Q1 2026), Neuraxis, INC reports quarterly revenue of $1.6M, net income of $-1.8M, free cash flow of $-1.2M. Top institutional holders of NRXS by reported 13-F value include AIGH Capital Management, Rosalind Advisors,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. NRXS trades on the NYSE exchange and files with the SEC under CIK 1933567. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NRXS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Neuraxis, INC directly from SEC EDGAR.

Revenue

Q1 2026

$1.6M

Net Income

Q1 2026

$-1.8M

Free Cash Flow

Q1 2026

$-1.2M

D/E Ratio

Q1 2026

0.02

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+32.9% YoY

$3.6MFY 2025

FY22 $2.7MFY23 $2.5MFY24 $2.7MFY25 $3.6M

Net Income

+5.4% YoY

$-7.8MFY 2025

FY22 $-4.8MFY23 $-14.6MFY24 $-8.2MFY25 $-7.8M

Operating Income

-9.4% YoY

$-7.8MFY 2025

FY22 $-3.4MFY23 $-6.7MFY24 $-7.2MFY25 $-7.8M

EPS (Diluted)

+22.1% YoY

$-0.95FY 2025

FY22 $-2.77FY23 $-4.50FY24 $-1.22FY25 $-0.95

Total Assets

+34.6% YoY

$6.4MFY 2025

FY22 $1.5MFY23 $509.5KFY24 $4.8MFY25 $6.4M

Total Debt

-3.8% YoY

$148.3KFY 2025

FY22 $228.3KFY23 $148.1KFY24 $154.2KFY25 $148.3K

Op. Cash Flow

-5.5% YoY

$-6.4MFY 2025

FY22 $-2.3MFY23 $-6.7MFY24 $-6.1MFY25 $-6.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Revenue	$3.6M +32.9%	$2.7M +9.2%	$2.5M -8.4%	$2.7M
Net Income	$-7.8M +5.4%	$-8.2M +43.7%	$-14.6M -206.0%	$-4.8M
Operating Income	$-7.8M -9.4%	$-7.2M -7.4%	$-6.7M -97.6%	$-3.4M
EPS (Diluted)	$-0.95 +22.1%	$-1.22 +72.9%	$-4.50 -62.5%	$-2.77
Total Assets	$6.4M +34.6%	$4.8M +833.8%	$509.5K -65.6%	$1.5M
Total Debt	$148.3K -3.8%	$154.2K +4.1%	$148.1K -35.2%	$228.3K
Operating Cash Flow	$-6.4M -5.5%	$-6.1M +8.9%	$-6.7M -191.3%	$-2.3M

AI Insight: NRXS Financial Trends

Revenue doubled to $2M in Q1 2026, but company remains unprofitable with persistent operating losses and negative cash flow.

• Revenue grew to $2M in Q1 2026 from $1M in prior quarters, marking first quarterly increase in tracked period.

• Operating income remains negative at $-2M in Q1 2026; no improvement despite revenue growth.

• Equity recovered to $6M in Q1 2026 from $0M in Q1 2025, suggesting capital infusion or reduced losses impact.

⚠ Operating cash flow negative or breakeven across all quarters; company burning cash despite revenue scale-up.

⚠ Net losses persisting at $-2M in Q1 2026 despite revenue doubling—margin expansion critical to viability.

AI Insight: NRXS Ratio Trends

Operating margin improved sharply to -108.3% in Q1 2026, signaling progress toward profitability after sustained triple-digit losses.

• Operating margin recovered 69.4pp from Q4 2025 (-177.3%) to Q1 2026 (-108.3%), largest sequential gain in dataset.

• Net profit margin followed similar trajectory, improving 67.0pp quarter-over-quarter to -109.5% in Q1 2026.

• Leverage remained benign, with D/E at 0.02 in Q1 2026, lowest in trailing twelve months, indicating minimal financial stress.

⚠ Company remains deeply unprofitable; TTM operating margin stands at -169.9%, and ROE at -126.7%.

⚠ ROIC data unavailable for recent quarters; unable to assess return on invested capital trends since Q2 2025.

Get alerted when NRXS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Neuraxis, INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NRXS

AIGH Capital Management LLC
$3.0M400,000 sh
Rosalind Advisors, Inc.
$1.7M286,138 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.7M225,867 sh
MONEY CONCEPTS CAPITAL CORP
$1.7M225,555 sh
Panoramic Capital, LLC
$1.4M190,000 sh
PARSONS CAPITAL MANAGEMENT INC/RI
$863.8K116,726 sh
GEODE CAPITAL MANAGEMENT, LLC
$689.2K93,105 sh
MARSHALL WACE, LLP
$582.3K78,695 sh
RENAISSANCE TECHNOLOGIES LLC
$569.5K76,954 sh
VANGUARD FIDUCIARY TRUST CO
$384.0K51,887 sh

Fund	Value	Shares
AIGH Capital Management LLC	$3.0M	400,000
Rosalind Advisors, Inc.	$1.7M	286,138
VANGUARD CAPITAL MANAGEMENT LLC	$1.7M	225,867
MONEY CONCEPTS CAPITAL CORP	$1.7M	225,555
Panoramic Capital, LLC	$1.4M	190,000
PARSONS CAPITAL MANAGEMENT INC/RI	$863.8K	116,726
GEODE CAPITAL MANAGEMENT, LLC	$689.2K	93,105
MARSHALL WACE, LLP	$582.3K	78,695
RENAISSANCE TECHNOLOGIES LLC	$569.5K	76,954
VANGUARD FIDUCIARY TRUST CO	$384.0K	51,887

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NRXS on your watchlist

Track score changes the day Neuraxis, INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NRXS a good stock to buy?

13F Pro's AI-powered analysis of Neuraxis, INC (NRXS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NRXS are available on the NRXS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NRXS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NRXS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Neuraxis, INC's investment landscape.